Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
For the nine months ended September 30, 2026, Lineage Cell Therapeutics reported total revenues of $4.2 million, a decrease from $7.9 million in the prior year, primarily due to lower collaboration revenues. The company significantly reduced its net loss compared to 2025, aided by a substantial $31.2 million non-cash gain from the change in fair value of warrant liabilities.
For the nine months ended September 30, 2026, Park Dental Partners reported revenue of $193.8 million, a 5.8% increase year-over-year, though net income decreased to $2.7 million from $5.4 million due to higher salaries and share-based compensation. The company maintained a solid liquidity position with $23.2 million in cash and cash equivalents while continuing to expand through dental practice acquisitions.
Rani Therapeutics received an additional 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement. As part of this process, the company's listing was transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective November 12, 2026. The company now has until May 10, 2027, to meet the requirement, which may involve a reverse stock split if necessary.
For the nine months ended September 30, 2026, Antares Strategic Credit Fund reported total investment income of $297.1 million and net investment income of $143.4 million. The fund's net asset value per share decreased to $25.02 from $25.42 at the end of 2025, primarily driven by $30.9 million in net realized and unrealized losses.
York Space Systems reported Q3 2026 revenue of $84.2 million and a significant net loss of $807.4 million, primarily driven by a $749.7 million non-cash goodwill impairment charge. The company highlighted a 30% expansion in its identified pipeline and the appointment of Brian Frantz as permanent CFO.
Term
Q3 2026
“Our identified pipeline grew more than 30 percent compared to last quarter, and we have secured the critical contract positions needed to compete for significant awards in 2027 and beyond, with IDIQ awards already converting into funded task orders.”
Dirk Wallinger, CEO of York
“Our contribution margins continue to benefit from the shift to newer programs, and we see a long-term trend toward increased profitability as we move up the value chain.”
Cardiff Oncology reported a net loss of $30.4 million for the nine months ended September 30, 2026, compared to $38.6 million in the prior year period. The company strengthened its balance sheet through the issuance of common stock and warrants, raising approximately $9.1 million in net proceeds during the third quarter of 2026.
The U.S. Court of Appeals for the Ninth Circuit partially reversed a lower court ruling, determining that Pacira BioSciences owes royalties to the Research Development Foundation (RDF) for EXPAREL manufactured using its 200-liter process. This decision impacts a previous $28.3 million recovery Pacira received and remands the case to the District Court to recalculate interest owed on other portions of the judgment.
For the nine months ended September 30, 2026, Everest Reinsurance Holdings reported net income of $797 million, an increase from $541 million in the prior year period, despite a decrease in earned premiums. The company's total stockholder's equity remained stable at $8.5 billion, as net income was largely offset by $793 million in other comprehensive losses primarily driven by unrealized depreciation of securities.
Scribe Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $174.2 million following its successful upsized IPO. The company is advancing its Phase 1 clinical trial for STX-1150, an epigenetic silencing therapy for LDL-C lowering, with initial data expected in the first half of 2027.
“This is a period of continued execution for Scribe, marked by the successful completion of our IPO and expansion of our collaboration with Sanofi to include the epigenetic silencing technology. Together, these milestones strengthen our foundation as we work to translate the potential of our technologies into meaningful medicines for patients.”
Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe Therapeutics
ProMIS Neurosciences reported a significant increase in cash to $44.1 million as of September 30, 2026, compared to $6.1 million at the end of 2025, primarily driven by financing activities that increased additional paid-in capital. The company's accumulated deficit grew to $158.5 million, reflecting ongoing research and development costs, while total shareholders' equity improved to a positive $41.8 million.
Crown Crafts reported second quarter fiscal 2027 results, with net income increasing to $1.3 million despite a decline in net sales to $19.0 million. The company achieved a significant gross margin expansion to 32.0%, driven by profitability initiatives and tariff refunds, and declared a quarterly dividend of $0.03 per share.
Term
Q2 2027
“We continue to execute well on our profitability initiatives with meaningful improvement this quarter in our gross profit, marketing and administrative expenses, and year-to-date operating cash flow.”
Olivia Elliott, President and Chief Executive Officer
“Our stronger profitability reflects our continued initiatives around efficiency and profitability, and our talented team is simultaneously focused on the development of additional higher-margin products and sales channels to grow both sales and profitability in the quarters ahead.”
Olivia Elliott, President and Chief Executive Officer
Farmer Mac's Board of Directors declared a quarterly dividend of $1.60 per share for all three classes of its common stock, payable on December 31, 2026. The Board also declared quarterly dividends for six series of its non-cumulative preferred stock (Series D, E, F, G, H, and I) payable in January 2027.
Dominos Pizza EVP, Chief Marketing Officer Katherine E. Trumbull Sells $122K of Stock
Katherine E. Trumbull, EVP, Chief Marketing Officer, sold 370 shares of Dominos Pizza Inc at $329.90 a share, worth $122K in total on Nov 10, 2026. Shares held after the trade: 5,785 (-6.0%).
Alpha Cognition Inc. appointed Caren Deardorf to its Board of Directors, effective November 11, 2026. Ms. Deardorf, a biotechnology executive with over 30 years of experience, will serve on the Audit and Governance and Nomination Committees. As part of her appointment, she received an initial grant of 755 restricted stock units and 1,020 stock options with an exercise price of $8.62 per share.
4D Molecular Therapeutics is a clinical-stage genetic medicine company reporting 56,379,402 shares of common stock outstanding as of November 9, 2026. The company continues to incur significant net losses and requires substantial additional capital to fund the development of its lead AAV product candidates, including 4D-150 and 4D-175.
Franklin Covey Chief Product Officer Michael Sean Merrill Covey Sells $123K of Stock
Michael Sean Merrill Covey, Chief Product Officer, sold 8,000 shares of Franklin Covey Co at $15.43 a share, worth $123K in total on Nov 10, 2026. Shares held after the trade: 217,426 (-3.5%).
AEVEX Corp. filed its 10-Q for the period ending September 30, 2026, highlighting the recent acquisition of Maritime Applied Physics Corporation (BlackSea) and its ongoing integration. The company continues to operate as a non-accelerated filer and emerging growth company following its April 2026 initial public offering.
Loews V.P., C.A.O. and Treasurer Mark S. Schwartz Sells $414K of Stock
Mark S. Schwartz, V.P., C.A.O. and Treasurer, sold 3,725 shares of Loews Corp at $111.17 a share, worth $414K in total on Nov 11, 2026. Shares held after the trade: 8,355 (-30.8%).
GCT Semiconductor reported total net revenues of $3.96 million for the nine months ended September 30, 2026, an increase from $2.11 million in the prior year period. Despite the revenue growth, the company incurred a net loss of $37.63 million for the period, driven by high operating expenses and a significant $9.23 million loss from the change in fair value of common stock warrant liabilities.
Electra Therapeutics is a clinical-stage biotechnology company focused on SIRP-targeted therapies, specifically its lead candidates ipsoprubart and ELA822. As of November 2026, the company remains pre-revenue with significant operating losses and expects to require substantial additional capital to fund its research and development programs.
York Space Systems Inc. appointed Brian D. Frantz as its permanent Chief Financial Officer, effective November 12, 2026. In connection with the appointment, the Board approved a compensation package including a $400,000 base salary, a 75% target bonus, and a prorated grant of 6,043 restricted stock units valued at approximately $1.5 million.
Colgate Palmolive EVP and Controller Gregory Malcolm Sells $402K of Stock
Gregory Malcolm, EVP and Controller, sold 4,100 shares of Colgate Palmolive Co at $97.97 a share, worth $402K in total on Nov 10, 2026. Shares held after the trade: 10,061 (-29.0%).
ICF International Chief Oper. & Fin. Officer James C. M. Morgan Sells $253K of Stock
James C. M. Morgan, Chief Oper. & Fin. Officer, sold 3,000 shares of ICF International, Inc. at $84.32 a share, worth $253K in total on Nov 10, 2026. Shares held after the trade: 46,683 (-6.0%).
Atrium Therapeutics reported a net loss of $41.1 million for the nine months ended September 30, 2026, compared to $20.4 million in the prior year period, driven by a significant increase in general and administrative expenses following its spin-off. The company ended the quarter with $232.1 million in cash, cash equivalents, and short-term investments, bolstered by a $313.4 million transfer from its former parent company.
U.S. Global Investors reported its first quarter fiscal 2027 results, achieving 18% revenue growth to $2.7 million and returning to operating profitability. The company saw a 14% year-over-year increase in average assets under management to $1.6 billion, driven largely by a 45% surge in gold and precious metals strategies.
Term
Q1 2027
“Gold miners continued to draw investor interest during the quarter, and that showed up in our asset levels. Average assets in our gold strategies are up more than 45% from a year ago. We believe disciplined, actively managed exposure to high-quality miners remains an important part of a diversified portfolio, and we’re pleased that more investors appear to agree.”
Frank Holmes, CEO and Chief Investment Officer
“Defense is no longer defined just by aircraft and ships. It’s increasingly being reshaped by artificial intelligence (AI), autonomous systems and cybersecurity. As governments around the world direct more spending toward national security, we believe WAR, our actively managed Smart Beta 2.0 ETF, gives investors targeted exposure to the companies driving that transformation.”
MediaAlpha repurchased 1,130,000 shares of its Class A common stock from an affiliate of White Mountains Insurance Group in a private transaction for approximately $16.0 million. The shares were purchased at $14.15 per share, representing a 5.5% discount to the previous day's closing price, and will be canceled and retired.
MultiSensor AI Holdings reported a net loss of $1.95 million for the quarter ended September 30, 2026, a slight increase from the $1.68 million loss in the prior year period. While nine-month revenue grew to $4.81 million from $4.16 million, the company continues to experience operating losses and negative cash flow from operations as it expands its SaaS capabilities and condition intelligence platform.
ProMIS Neurosciences reported Q3 2026 financial results, ending the period with $44.1 million in cash which is expected to fund operations through 2027. The company reaffirmed that topline data from its Phase 1b PRECISE-AD trial of PMN310 in Alzheimer’s disease remains on track for the first quarter of 2027.
Term
Q3 2026
“The third quarter of 2026 has been productive for ProMIS, following encouraging interim data from our Phase 1b PRECISE-AD trial in Alzheimer’s disease (AD). Based on data generated to date, we continue to believe PMN310 offers a differentiated approach by selectively targeting the most toxic and destructive form of amyloid-beta, the oligomers.”
Neil Warma, President and Chief Executive Officer
“With PRECISE-AD closing out its final stage of patient visits, we look forward to reporting topline data in the first quarter of 2027, which will include safety, biomarker and clinical efficacy measures.”
Ryan J. Leib, CAO, sold 6,963 shares of Vertex, Inc. at $17.39 a share, worth $121K in total on Nov 9, 2026. Shares held after the trade: 810 (-89.6%).